Moving to the resistance to combined EGFR + KRAS G12C blockade in CRC, even in this case most mechanisms converge on RAS-MAPK pathway reactivation either by de novo mutations or by parallel signaling through other RTKs [90]. The gene discussed is KRAS; the disease is colorectal carcinoma.